Have you taken part in the clinical trial for donanemab?
Alzheimer’s Society is preparing an evidence submission to NICE for their appraisal of donanemab, and would like to hear from people with direct experience of the drug to help inform our submission.
In particular, we are interested in hearing views on what you think are the advantages and disadvantages of the drug. Responses would be used in our evidence submission which will be shared with NICE and published on the NICE website. We would state that responses are from trial participants, but we would not use individual’s names.
Please let us know if you have taken part in the trial and would be happy to share your views with us, to contribute to this important appraisal.
Thanks everyone
Alzheimer’s Society is preparing an evidence submission to NICE for their appraisal of donanemab, and would like to hear from people with direct experience of the drug to help inform our submission.
In particular, we are interested in hearing views on what you think are the advantages and disadvantages of the drug. Responses would be used in our evidence submission which will be shared with NICE and published on the NICE website. We would state that responses are from trial participants, but we would not use individual’s names.
Please let us know if you have taken part in the trial and would be happy to share your views with us, to contribute to this important appraisal.
Thanks everyone
